Skip to main content

Table 2 Identification of KRAS mutation in patient cohorts using different methods

From: A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients

Cohort

Total KRAS Mutation Identified (Codon 12 & 61)

Method

Tumour Type

KRAS Mutation Frequency

Total KRAS mutation Frequency

Discovery Cohort (n = 8)

N = 1

NGS

PDAC (n = 5)

0%

12%

PAC (n = 3)

33% (n = 1)

Validation Cohort (n = 85)/ (n = 75)a

N = 16

Sanger Sequencing

PDAC (n = 25)

32%(n = 8)

19%

PAC (n = 50)

14% (n = 6)

PCR-RFLP of 12th Codon

PDAC (n = 25)

32%(n = 8)

19%

PAC (n = 50)

14% (n = 6)

ASPCR

PDAC (n = 25)

36%(n = 9)

20%

PAC (n = 50)

12% (n = 6)

Independent Patient Cohort (n = 24)

N = 8

PCR-RFLP of 12th Codon

PDAC (n = 24)

33% (n = 8)

33%

  1. aIn case of validation cohort PCR amplification of KRAS exon 2 for 10 samples could not performed due to technical error